The 1-year survival rate for ipilimumab plus sargramostim was 68.9 % ( 95 % CI , 60.6 % -85.5 % ) compared to 52.9 % ( 95 % CI , 43.6 % -62.2 % ) for ipilimumab alone ( stratified log-rank 1-sided P = .01 ; mortality hazard ratio 0.64 [ 1-sided 90 % repeated CI , not applicable-0 .90 ] ) .